Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder.

Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE.

Mol Diagn Ther. 2018 Oct;22(5):571-593. doi: 10.1007/s40291-018-0352-x. Review.

2.

Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.

Frye RE, Rossignol DA.

Clin Med Insights Pediatr. 2016 Jun 15;10:43-56. doi: 10.4137/CMPed.S38337. eCollection 2016. Review.

3.

The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review.

Rossignol DA, Frye RE.

Front Pediatr. 2014 Aug 22;2:87. doi: 10.3389/fped.2014.00087. eCollection 2014. Review.

4.

Treatments for biomedical abnormalities associated with autism spectrum disorder.

Frye RE, Rossignol DA.

Front Pediatr. 2014 Jun 27;2:66. doi: 10.3389/fped.2014.00066. eCollection 2014. Review.

5.

Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism.

Rossignol DA, Frye RE.

Front Physiol. 2014 Apr 22;5:150. doi: 10.3389/fphys.2014.00150. eCollection 2014. Review.

6.

Environmental toxicants and autism spectrum disorders: a systematic review.

Rossignol DA, Genuis SJ, Frye RE.

Transl Psychiatry. 2014 Feb 11;4:e360. doi: 10.1038/tp.2014.4. Review.

7.

My experience learning about autism.

Rossignol DA.

Glob Adv Health Med. 2013 Nov;2(6):74-7. doi: 10.7453/gahmj.2013.090.

8.

Melatonin in autism spectrum disorders.

Rossignol DA, Frye RE.

Curr Clin Pharmacol. 2014;9(4):326-34. Review.

PMID:
24050742
9.

Hyperbaric oxygen treatment in autism spectrum disorders.

Rossignol DA, Bradstreet JJ, Van Dyke K, Schneider C, Freedenfeld SH, O'Hara N, Cave S, Buckley JA, Mumper EA, Frye RE.

Med Gas Res. 2012 Jun 15;2(1):16. doi: 10.1186/2045-9912-2-16.

10.

Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis.

Rossignol DA.

Med Gas Res. 2012 Mar 15;2(1):6. doi: 10.1186/2045-9912-2-6.

11.

Cerebral folate receptor autoantibodies in autism spectrum disorder.

Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA.

Mol Psychiatry. 2013 Mar;18(3):369-81. doi: 10.1038/mp.2011.175. Epub 2012 Jan 10.

13.

Substantial problems with measuring brain mitochondrial dysfunction in autism spectrum disorder using magnetic resonance spectroscopy.

Rossignol DA, Frye RE.

J Autism Dev Disord. 2012 Apr;42(4):640-2; author reply 643-6. doi: 10.1007/s10803-011-1276-z. No abstract available.

PMID:
21556966
14.

Melatonin in autism spectrum disorders: a systematic review and meta-analysis.

Rossignol DA, Frye RE.

Dev Med Child Neurol. 2011 Sep;53(9):783-792. doi: 10.1111/j.1469-8749.2011.03980.x. Epub 2011 Apr 19. Review.

15.

Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders.

Frye RE, Rossignol DA.

Pediatr Res. 2011 May;69(5 Pt 2):41R-7R. doi: 10.1203/PDR.0b013e318212f16b. Review.

16.

Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

Rossignol DA, Frye RE.

Mol Psychiatry. 2012 Mar;17(3):290-314. doi: 10.1038/mp.2010.136. Epub 2011 Jan 25. Review.

17.
18.

Autism spectrum disorders: rising prevalence drives research on causes and cures.

Gupta S, Rossignol DA.

Ann Clin Psychiatry. 2009 Oct-Dec;21(4):193. No abstract available.

PMID:
19938392
19.

Novel and emerging treatments for autism spectrum disorders: a systematic review.

Rossignol DA.

Ann Clin Psychiatry. 2009 Oct-Dec;21(4):213-36. Review.

PMID:
19917212
20.

Autism spectrum disorders: navigating in uncharted waters.

Gupta S, Rossignol DA.

Ann Clin Psychiatry. 2009 Jul-Sep;21(3):129-30. No abstract available.

PMID:
19771665

Supplemental Content

Loading ...
Support Center